|Bid||39.00 x 800|
|Ask||55.00 x 1000|
|Day's Range||43.81 - 44.22|
|52 Week Range||40.49 - 58.00|
|Beta (5Y Monthly)||0.37|
|PE Ratio (TTM)||19.91|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for QGEN
BD's (BDX) new molecular RUO PCR assay is expected to aid in better managing the ongoing global monkeypox outbreak.
Quest Diagnostics in its latest media report notes that demand for COVID-19 molecular diagnostic testing declined in August compared to the prior month.
Investors are optimistic about QIAGEN's (QGEN) better-than-expected results and solid genomics uptake.